



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.03.2018 Bulletin 2018/11

(51) Int Cl.:
A61M 37/00 (2006.01) **A61B 8/08 (2006.01)**
A61K 9/00 (2006.01) **A61K 49/22 (2006.01)**

(21) Application number: **16188600.7**

(22) Date of filing: **13.09.2016**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
 Designated Extension States:
BA ME
 Designated Validation States:
MA MD

- **Yeh, Chih-Kuang**
Hsinchu (TW)
- **Kang, Shih-Tsung**
22048 New Taipei City (TW)
- **Hsieh, Zong-Han**
413 Taichung City (TW)

(71) Applicant: **National Tsing Hua University**
Hsinchu (TW)

(74) Representative: **Lang, Christian**
LangPatent Anwaltskanzlei
IP Law Firm
Rosenheimer Straße 139
81671 München (DE)

(72) Inventors:
 • **Lo, Wei-Chen**
970 Hualien County (TW)

Remarks:
 Amended claims in accordance with Rule 137(2) EPC.

(54) **ULTRASONIC DEVICE FOR TRANSVERSELY MANIPULATING DRUG DELIVERY CARRIERS**

(57) An ultrasonic device 100 for transversely manipulating drug delivery carriers 300 includes a driving unit 102 and a transducer 104. The transducer is electrically connected to the driving unit and has a piezoelectric sheet 1042 in a curved shape. The piezoelectric sheet

includes a plurality of channels 1042a, 1042b, 1042c, 1042d, and a phase difference is generated between every two of the channels by the driving unit for producing an acoustic vortex.




Fig. 2C

Description**BACKGROUND**

Technical Field

[0001] The present disclosure relates to an ultrasonic device. More particularly, the present disclosure relates to an ultrasonic device for transversely manipulating drug delivery carriers and a method using the same.

Description of Related Art

[0002] In present medical technology, delivering the drug to a lesion zone without passing the metabolism of the digestive system and the liver to maintain the concentration of the drug in the blood is a concerned research subject. However, it is difficult to deliver the drug to the lesion zone directly.

[0003] A drug delivery carrier is any substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug delivery carriers are primarily used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. However, the drug delivery carriers still cannot be delivered precisely so as to influence a local concentration of the drug delivery carriers at the lesion zone.

[0004] Manipulation of drug delivery carriers, such as microbubbles, cells and droplets, based on acoustic wave has become significant interest in biological and biomedical research due to their non-contact and non-invasive characters. The gas-filled microbubbles are encapsulated by an elastic shell and have great potential applications in drug delivery and targeted imaging. Transportation and trapping of the microbubbles to desired positions can improve the local concentration of the microbubbles in targeted areas and provide more efficient bonding.

[0005] One of current methods for manipulating the microbubbles is performed by a standing acoustic wave. The standing acoustic wave has become a powerful and active strategy to levitate or manipulate single or multiple particles and even living animals. However, forming the standing wave pattern has the nature of mandatory and environment dependent, and thus that limits the possibilities to manipulate an object in real applications. Another one of the current methods for manipulating the microbubbles is performed by a single-beam acoustic tweezer with a high frequency of more than 40MHz. However, the high frequency is not suitable to be applied on the human body.

SUMMARY

[0006] The present disclosure provides an ultrasonic device for transversely manipulating drug delivery carriers includes a driving unit and a transducer. The transducer is electrically connected to the driving unit and has a piezoelectric sheet in a curved shape. The piezoelectric sheet includes a plurality of channels, and a phase difference is generated between every two of the channels by the driving unit for producing an acoustic vortex.

[0007] According to the ultrasonic device for transversely manipulating drug delivery carriers of the present disclosure, the piezoelectric sheet has a curvature radius ranged from 10 mm to 100 mm. In particular, the piezoelectric sheet is made of lead zirconate titanate.

[0008] According to the ultrasonic device for transversely manipulating drug delivery carriers of the present disclosure, the transducer further comprises a case. The case is provided for sealing the piezoelectric sheet and filled with epoxy.

[0009] According to the ultrasonic device for transversely manipulating drug delivery carriers of the present disclosure, the driving unit comprises a pulse generator.

[0010] According to the ultrasonic device for transversely manipulating drug delivery carriers of the present disclosure, the drug delivery carriers comprise a plurality of microbubbles.

[0011] The present disclosure further provides a method for transversely manipulating drug delivery carriers, and the method includes the following steps. First, an ultrasonic executing step is performed for producing the acoustic vortex by the ultrasonic device as mentioned above. A focusing step is performed for focusing the drug delivery carriers toward a center of the acoustic vortex, and a manipulating step is then performed for manipulating the drug delivery carriers to a lesion zone.

[0012] According to the method for transversely manipulating drug delivery carriers of the present disclosure, the piezoelectric sheet of the ultrasonic device has a curvature radius ranged from 10 mm to 100 mm.

[0013] According to the method for transversely manipulating drug delivery carriers of the present disclosure, the ultrasonic executing step is performed by a pulse generator with a frequency ranged from 3 MHz to 20 MHz. Furthermore, the ultrasonic executing step is performed by a pulse generator with a duty cycle of 30 % or above. More particular, the phase difference is ranged from $\pi/8$ to $\pi/2$.

[0014] According to the method for transversely manipulating drug delivery carriers of the present disclosure, the drug delivery carriers comprise a plurality of microbubbles. In particular, an average particle size of the microbubbles is ranged from 1 μm to 200 μm . Furthermore, each of the microbubbles is a phospholipid-coated microbubble. More particular, each of the microbubbles comprises an ultrasound contrast agent or a drug.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The present disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:

Fig. 1A is a schematic drawing of an ultrasonic device for transversely manipulating drug delivery carriers according to one embodiment of the present disclosure;

Fig. 1B is a schematic drawing of a piezoelectric sheet according to one embodiment of the present disclosure;

Fig. 2A is a flow chart of a method for transversely manipulating drug delivery carriers according to one embodiment of the present disclosure;

Fig. 2B is a schematic drawing showing an operation mode of the ultrasonic device in Fig. 1 A;

Fig. 2C is a schematic drawing showing the method for transversely manipulating drug delivery carriers of Step S204 in Fig. 2A;

Fig. 3A is an axial measured result of a vortex acoustic field according to Example 1 of the present disclosure;

Fig. 3B is a transverse measured result of the vortex acoustic field of Fig. 3A;

Fig. 4A is an image showing microbubbles in a needle hydrophone without applying the acoustic vortex according to Example 1 of the present disclosure;

Figs. 4B~4D are images showing the microbubbles of Fig. 4A with applying the acoustic vortex;

Fig. 4E is an image showing a trajectory of a microbubbles cluster manipulated by the ultrasonic device of Fig. 1 A;

Fig. 5A is an image showing a counterclockwise manipulation of a microbubbles cluster;

Fig. 5B is an image showing a clockwise manipulation of a microbubbles cluster; and

Fig. 6 is an image showing a manipulation of microbubbles in a needle hydrophone with a high flow rate according to Example 2 of the present disclosure.

DETAILED DESCRIPTION

[0016] The present disclosure provides an ultrasonic

device for transversely manipulating drug delivery carriers and allows collect and manipulation microbubbles in a desired position. The low frequency, appropriate working distance for veins, arteries or a deep tissue of the human body, and single-beam configuration provide superior usefulness compared with the conventional methods particularly in drug delivery applications.

[0017] Please refer to Fig. 1A and Fig. 1B. Fig. 1A is a schematic drawing of an ultrasonic device 100 for transversely manipulating drug delivery carriers according to one embodiment of the present disclosure, and Fig. 1B is a schematic drawing of a piezoelectric sheet 1042 according to one embodiment of the present disclosure. As shown in Fig. 1A, the ultrasonic device 100 for transversely manipulating drug delivery carriers at least includes a driving unit 102 and a transducer 104. The transducer 104 is electrically connected to the driving unit 102. Furthermore, the transducer 104 has a piezoelectric sheet 1042, and the piezoelectric sheet 1042 is in a curved shape and includes a plurality of channels (please refer to Fig. 1 B). A phase difference is generated between every two of the channels by the driving unit for producing an acoustic vortex (not shown in the figure).

[0018] In particular, the driving unit 102 can be a pulse generator. More particularly, the driving unit 102 can be but not limited to a field-programmable gate array (FPGA)-based pulse generator. In addition, a driving signal transmitted by the driving unit 102 can be a square-wave signal or a sine wave signal. Although an amplifier is not shown in the figure, the amplifier can be disposed between the driving unit 102 and the transducer 104 for amplifying the driving signal.

[0019] In particular, the transducer 104 can be an array-based transducer. Thus, as shown in Fig. 1B, the piezoelectric sheet 1042 is cut into four adjacent channels, that is, channel 1042a, channel 1042b, channel 1042c and channel 1042d. In addition, the channel 1042a, channel 1042b, channel 1042c and channel 1042d can be obtained by a laser cutting method so as to maintain characteristics of the piezoelectric sheet 1042. However, the present disclosure is not limited thereto. The piezoelectric sheet 1042 also can be cut into eight adjacent channels.

[0020] In details, the transducer 104 further includes a case 1044 for sealing the piezoelectric sheet 1042 therein. According to one embodiment of the present disclosure, the piezoelectric sheet 1042 is made of lead zirconate titanate (PZT), and the case 1044 is made of acrylic material. Moreover, the case 1044 can be filled with epoxy, but the present disclosure is not limited thereto.

[0021] It is noted that the piezoelectric sheet 1042 has a curvature radius ranged from 10 mm to 100 mm. In details, a focal length of the piezoelectric sheet 1042, that is, the working distance of the transducer 104, is ranged from 10 mm to 100 mm. More particularly, the curvature radius of the piezoelectric sheet 1042 is ranged from 10 mm to 30 mm. Such the working distance of the transducer 104 is short enough to be applied in the veins

or arteries of the human body, a micro-electro-mechanical system, or a microscopic scale.

[0022] Please refer to Fig. 2A, Fig. 2B and Fig. 2C. Fig. 2A is a flow chart of a method for transversely manipulating drug delivery carriers according to one embodiment of the present disclosure, Fig. 2B is a schematic drawing showing an operation mode of the ultrasonic device 100 in Fig. 1A, and Fig. 2C is a schematic drawing showing the method for transversely manipulating drug delivery carriers of Step S204 in Fig. 2A. As shown in Fig. 2A, the present disclosure further provides a method for transversely manipulating drug delivery carriers, and the method includes Step S202, Step S204 and Step S206.

[0023] Step S202 is an ultrasonic executing step. As mentioned above, the transducer 104 of the present disclosure can adopt the piezoelectric sheet 1042 with four channels as shown in Fig. 2B. It is noted that the piezoelectric sheet 1042 of the present disclosure needs to be in the curved shape although it seems a planar sheet in Fig. 2B for further illustration. In Step S202, the piezoelectric sheet 1042 can be driven with $\pi/2$ -rad phase difference along the beam axis to produce an acoustic vortex. That is, the phase difference of $\pi/2$ is generated between every two of the channel 1042a, channel 1042b, channel 1042c and channel 1042d. However, the above-mentioned phase difference can be ranged from $\pi/8$ to $\pi/2$ and is not limited thereto. Accordingly, each channel could be manually controlled so that the present disclosure has less limitation for application.

[0024] Step S204 is a focusing step. As shown in Fig. 2C, for simulating the application in the human body, the drug delivery carriers 300 can be suspended in a vessel phantom 400, such as a vein phantom or an artery phantom, and flow along with a direction F of a fluid filled in the vessel phantom 400. Thus, Step S204 is provided for creating a steep potential distribution in a center of the vortex so as to focus the drug delivery carriers 300 toward the center of the acoustic vortex to form a microbubbles cluster 320.

[0025] Step S206 is a manipulating step for manipulating the drug delivery carriers 300 to a lesion zone (not shown in the figure).

[0026] In details, Step S202 is performed by the driving unit, preferably a pulse generator, with a frequency ranged from 3 MHz to 20 MHz, preferably from 3 MHz to 5 MHz. Accordingly, such the low frequency is suitable to be applied in the human body. Furthermore, Step S202 is performed by the pulse generator with a duty cycle of 30 % or above.

[0027] Moreover, the drug delivery carriers of the present disclosure are a plurality of microbubbles. In particular, an average particle size of the microbubbles is ranged from 1 μm to 200 μm . Furthermore, each of the microbubbles comprises an ultrasound contrast agent or a drug. It is noted that each of the microbubbles is an elastomer and can generate a cavitation with the acoustic vortex so as to be controlled by a radiation force.

[0028] The ultrasonic device for transversely manipulating drug delivery carriers and the method using the same have been described as mentioned above. In the following, Example 1 and example 2 will be further provided to illustrate transmit conditions of the abovementioned ultrasonic device 100, the method using the same, and the effects of the present disclosure in details.

<Example 1>

[0029] In Example 1, the driving unit is a FPGA-based pulse generator a phase shift of 2π . The vortex acoustic field generated is measured at two different observation planes using a 200 μm needle hydrophone (HG-0085, Onda, Sunnyvale, USA) mounted on a 3-D computer controlled motor system. Herein, the needle hydrophone is used as a vessel phantom, such as a vein phantom or an artery phantom, for simulating the application in the human body. Furthermore, the piezoelectric sheet of the transducer has four channels. More particularly, a curvature radius of the piezoelectric sheet is 20 mm.

[0030] In Example 1, each of the microbubbles is used as the drug delivery carrier, respectively, and can be a phospholipid-coated microbubble. More particularly, the microbubbles are fabricated by using the compositions of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DP-PC), 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DSPG), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] (DEPE-PEG5000). However, the present disclosure is not limited thereto.

[0031] In brief, the center of the acoustic vortex where all phases are perfect destructive interference results from the beam axis so as to form a potential well. In Example 1, the microbubbles are exposed to the acoustic vortex at one fourth the Rayleigh distance (RD/4) from the transducer. When the microbubbles are subjected into a fluid of the needle hydrophone and the vortex acoustic field is applied, the oscillating pressure gradient can couple with the bubble oscillations to produce the radiation force. Thus, each of the microbubbles will be trapped at the potential well and then transported. The motion of each microbubble can be recorded with B-mode imaging using a clinical ultrasound imaging system (model t3000, Terason, USA), however, the present disclosure is not limited thereto. Other transmit parameters of the driving unit are listed in Table 1.

Table 1

Frequency (MHz)	3
Waveform	Sinusoid
Pulse duration (cycle)	1000
Duty cycle (%)	33
Acoustic pressure (kPa)	40

[0032] Please refer to Fig. 3A and Fig. 3B. Fig. 3A is an axial measured result of a vortex acoustic field according to Example 1 of the present disclosure, and Fig. 3B is a transverse measured result of the vortex acoustic field of Fig. 3A. As shown in Fig. 3A, the focal length of the vortex acoustic field is 2 cm. That is, the manipulation of the microbubbles using the ultrasonic device provided in Example 1 has a shorter working distance so as to be applied in the micro-electro-mechanical system or the microscopic scale easily. Furthermore, the acoustic vortex refers to a type of beam having a helicoidal wavefront, and hence the beam has a central dark core H of zero amplitude surrounded by a high intensity ring as shown in Fig. 3B.

[0033] Please refer to Figs. 4A~4D. Fig. 4A is an image showing microbubbles 300 in a needle hydrophone without applying the acoustic vortex according to Example 1 of the present disclosure, and Figs. 4B~4D are images showing the microbubbles 300 of Fig. 4A with applying the acoustic vortex. As shown in Fig. 4A, the microbubbles 300 are suspended in the fluid of the needle hydrophone and flow along the direction F of the fluid, which has a volume velocity of 0.5 mL/hr, when the ultrasonic device is not applied and the acoustic vortex has not been produced yet. When the ultrasonic device is applied on a target zone T, which is represented by a dotted line, to produce the acoustic vortex, the microbubbles 300 start to swirling toward a center of the acoustic vortex as shown in Fig. 4B and Fig. 4C. Finally, a microbubbles cluster 320 will be formed in the target zone T as shown in Fig. 4D.

[0034] Please refer to Fig. 4E, which is an image showing a trajectory of the microbubbles cluster 320 manipulated by the ultrasonic device 100 of Fig. 1A. As shown in Fig. 4E, the microbubbles cluster 320 can be manipulated to move along with the motions of the transducer. That is, the acoustic vortex provides the capability of 2-D particles manipulation.

[0035] Please further refer to Fig. 5A and Fig. 5B. Fig. 5A is an image showing a counterclockwise manipulation of the microbubbles cluster 320, and Fig. 5B is an image showing a clockwise manipulation of the microbubbles cluster 320. In Fig. 5A, from left to right and from up to down, the microbubbles cluster 320 can be manipulated to perform a counterclockwise rotation. In Fig. 5B, from left to right and from up to down, the microbubbles cluster 320 also can be manipulated to perform a clockwise rotation. That is to say, except for the transportation, the acoustic vortex of the present disclosure also can manipulate the microbubbles cluster to rotate.

<Example 2>

[0036] Example 2 is provided for simulating the manipulation of the microbubbles under a high flow rate, for example, the manipulation in the artery. The ultrasonic device and the method for manipulating the drug delivery carriers of Example 2 are similar to Example 1 except

the transmit parameters. The transmit parameters are further listed in Table 2.

Table 2

Frequency (MHz)	3
Waveform	Sinusoid
Pulse duration (cycle)	1000
Duty cycle (%)	99
Acoustic pressure (kPa)	800

[0037] Please refer to Fig. 6, which is an image showing a manipulation of microbubbles in a needle hydrophone with a high flow rate according to Example 2 of the present disclosure. In Example 2, it is noted that the microbubbles (not shown in the figure) still can be trapped to form a microbubbles cluster 520 even though the flow rate of the fluid in the needle hydrophone is 5 mL/hr. That is, the ultrasonic device and the method for manipulating the drug delivery carriers disclosed in the present disclosure can be applied but not limited to the artery, where has a high flow rate of blood, of the human body.

[0038] To sum up, the present disclosure provides an ultrasonic device for transversely manipulating drug delivery carriers and allows collect and manipulation microbubbles in a desired position. The low frequency, appropriate working distance for veins, arteries or a deep tissue of the human body, and single-beam configuration provide superior usefulness compared with the conventional methods particularly in drug delivery applications. Moreover, the trapping characteristics may be useful to increase the efficiency of microbubbles accumulation at the lesion zone.

Claims

1. An ultrasonic device (100) for transversely manipulating drug delivery carriers (300), comprising:

a driving unit (102); and
a transducer (104) electrically connected to the driving unit (102) and having a piezoelectric sheet (1042) in a curved shape, wherein the piezoelectric sheet (1042) comprises a plurality of channels (1042a, 1042b, 1042c, 1042d) and a phase difference is generated between every two of the channels (1042a, 1042b, 1042c, 1042d) by the driving unit (102) for producing an acoustic vortex.

2. The ultrasonic device (100) of claim 1, wherein the piezoelectric sheet (1042) has a curvature radius ranged from 10 mm to 100 mm.
3. The ultrasonic device (100) of claim 1, wherein the

piezoelectric sheet (1042) is made of lead zirconate titanate.

4. The ultrasonic device (100) of claim 1, wherein the transducer (104) further comprises:

a case (1044) provided for sealing the piezoelectric sheet (1042) and filled with epoxy.

5. The ultrasonic device (100) of claim 1, wherein the driving unit (102) comprises a pulse generator.

6. The ultrasonic device (100) of claim 1, wherein the drug delivery carriers (300) comprise a plurality of microbubbles (300).

7. A method for transversely manipulating drug delivery carriers (300), comprising:

performing an ultrasonic executing step (S202) for producing the acoustic vortex by the ultrasonic device (100) of claim 1;
performing a focusing step (S204) for focusing the drug delivery carriers (300) toward a center of the acoustic vortex; and
performing a manipulating step (S206) for manipulating the drug delivery carriers (300) to a lesion zone.

8. The method of claim 7, wherein the piezoelectric sheet (1042) of the ultrasonic device (100) has a curvature radius ranged from 10 mm to 100 mm.

9. The method of claim 8, wherein the ultrasonic executing step (S202) is performed by a pulse generator with a frequency ranged from 3 MHz to 20 MHz.

10. The method of claim 8, wherein the ultrasonic executing step (S202) is performed by a pulse generator with a duty cycle of 30 % or above.

11. The method of claim 8, wherein the phase difference is ranged from $\pi/8$ to $\pi/2$.

12. The method of claim 7, wherein the drug delivery carriers (300) comprise a plurality of microbubbles (300).

13. The method of claim 12, wherein an average particle size of the microbubbles (300) is ranged from 1 μm to 200 μm .

14. The method of claim 12, wherein each of the microbubbles (300) is a phospholipid-coated microbubble.

15. The method of claim 12, wherein each of the microbubbles (300) comprises an ultrasound contrast agent or a drug.

Amended claims in accordance with Rule 137(2) EPC.

1. An ultrasonic device (100) for transversely manipulating drug delivery carriers (300), comprising:

a driving unit (102); and
a transducer (104) electrically connected to the driving unit (102) and having a piezoelectric sheet (1042) in a curved shape, wherein the piezoelectric sheet (1042) comprises a plurality of channels (1042a, 1042b, 1042c, 1042d),

characterised in that

a phase difference is generated between every two of the channels (1042a, 1042b, 1042c, 1042d) by the driving unit (102) for producing an acoustic vortex.

2. The ultrasonic device (100) of claim 1, wherein the piezoelectric sheet (1042) has a curvature radius ranged from 10 mm to 100 mm.

3. The ultrasonic device (100) of claim 1, wherein the piezoelectric sheet (1042) is made of lead zirconate titanate.

4. The ultrasonic device (100) of claim 1, wherein the transducer (104) further comprises:

a case (1044) provided for sealing the piezoelectric sheet (1042) and filled with epoxy.

5. The ultrasonic device (100) of claim 1, wherein the driving unit (102) comprises a pulse generator.

6. The ultrasonic device (100) of claim 1, wherein the drug delivery carriers (300) comprise a plurality of microbubbles (300).

7. The ultrasonic device (100) of claim 5, wherein the pulse generator is operated with a frequency ranging from 3 MHz to 20 MHz.

8. The ultrasonic device (100) of claim 5, wherein the pulse generator is operated with a duty cycle of 30 % or above.

9. The ultrasonic device (100) of claim 1, wherein the phase difference ranges from $\pi/8$ to $\pi/2$.

10. The ultrasonic device (100) of claim 6, wherein an average particle size of the microbubbles (300) ranges from 1 μm to 200 μm .

11. The ultrasonic device (100) of claim 6, wherein each of the microbubbles (300) is a phospholipid-coated microbubble.

12. The ultrasonic device (100) of claim 6, wherein each of the microbubbles (300) comprises an ultrasound contrast agent or a drug.

5

10

15

20

25

30

35

40

45

50

55

7




Fig. 1A




Fig. 1B




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 3A




Fig. 3B




Fig. 4A

Fig. 4C




Fig. 4B

Fig. 4D




Fig. 4E




Fig. 5A




Fig. 5B




Fig. 6



EUROPEAN SEARCH REPORT

Application Number
EP 16 18 8600

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	US 6 029 518 A (OEFTERING RICHARD C [US]) 29 February 2000 (2000-02-29) * column 1, line 6 - column 12, line 25; figures 1-13 *	1-15	INV. A61M37/00 A61B8/08 A61K9/00 A61K49/22
X	----- WO 2013/140175 A1 (UNIV LEEDS [GB]) 26 September 2013 (2013-09-26) * page 1, line 3 - page 17, line 15; figures 1-8 *	1,2,5-15	
X	----- US 2016/250457 A1 (BOCK ROBERT T [US]) 1 September 2016 (2016-09-01) * page 1, paragraph 2 - page 4, paragraph 58; figures 1-8 *	1-15	
X	----- US 2013/046229 A1 (KONOFAGOU ELISA E [US] ET AL) 21 February 2013 (2013-02-21) * page 1, paragraph 3 - page 17, paragraph 172; figures 1-22 *	7-15	
A	-----	1-6	
			TECHNICAL FIELDS SEARCHED (IPC)
			A61M A61B A61K
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
Berlin		22 February 2017	Rolland, Philippe
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 16 18 8600

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-02-2017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6029518 A	29-02-2000	NONE	

WO 2013140175 A1	26-09-2013	NONE	

US 2016250457 A1	01-09-2016	NONE	

US 2013046229 A1	21-02-2013	EP 2480144 A1	01-08-2012
		US 2013046229 A1	21-02-2013
		US 2016346526 A1	01-12-2016
		WO 2011035312 A1	24-03-2011

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

专利名称(译)	用于横向操纵药物递送载体的超声波装置		
公开(公告)号	EP3292882A1	公开(公告)日	2018-03-14
申请号	EP2016188600	申请日	2016-09-13
[标]申请(专利权)人(译)	国立清华大学		
申请(专利权)人(译)	清大		
当前申请(专利权)人(译)	清大		
[标]发明人	LO WEI CHEN YEY CHIH KUANG KANG SHIH TSUNG HSIEH ZONG HAN		
发明人	LO, WEI-CHEN YEY, CHIH-KUANG KANG, SHIH-TSUNG HSIEH, ZONG-HAN		
IPC分类号	A61M37/00 A61B8/08 A61K9/00 A61K49/22		
CPC分类号	A61B8/0891 A61B8/481 A61K9/0009 A61M37/0092 A61N7/00 A61N2007/0039 A61N2007/0065		
代理机构(译)	LANG , CHRISTIAN		
审查员(译)	ROLLAND , PHILIPPE		
其他公开文献	EP3292882B1		
外部链接	Espacenet		

摘要(译)

用于横向操纵药物输送载体300的超声装置100包括驱动单元102和换能器104.换能器电连接到驱动单元并具有弯曲形状的压电片1042。压电片包括多个通道1042a, 1042b, 1042c, 1042d, 并且通过用于产生声涡的驱动单元在每两个通道之间产生相位差。




Fig. 2C